Indian arm of global AstraZeneca; markets Oncology, Biopharmaceuticals and Rare Disease medicines.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 359 | 451 | 506 | 584 | 707 | 765 | 794 | 868 |
| Borrowings | 12 | 12 | 9 | 7 | 5 | 36 | 35 | 111 |
| Other Liabilities | 330 | 306 | 337 | 389 | 362 | 712 | 781 | 1.0k |
| Total Liabilities | 706 | 775 | 857 | 985 | 1.1k | 1.5k | 1.6k | 2.0k |
| AssetsFixed Assets | 72 | 81 | 74 | 69 | 67 | 64 | 40 | 117 |
| CWIP | 24 | 4 | 2 | 1 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 611 | 690 | 780 | 915 | 1.0k | 1.5k | 1.6k | 1.9k |
| Total Assets | 706 | 775 | 857 | 985 | 1.1k | 1.5k | 1.6k | 2.0k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 55 | 87 | 105 | 101 | 58 | 28 | 65 | -15 |
| Cash from Investing | 4 | -171 | 173 | 5 | 18 | 22 | 31 | 19 |
| Cash from Financing | 0 | -6 | -9 | -9 | -24 | -44 | -66 | -92 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | 37 | 74 | 99 | 94 | 53 | 18 | 64 | -18 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (114.0×) and current (107.0×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 23.8% growth and a 107× exit, ₹8024 only delivers your return if you pay ₹10,687. The price is currently baking in 18% growth.
EPS grows 23.8%/yr for 5 years, then fades to 6% over 2, exits at 107×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 23.8% | 92.86 |
| FY28 | 23.8% | 114.96 |
| FY29 | 23.8% | 142.32 |
| FY30 | 23.8% | 176.20 |
| FY31 | 23.8% | 218.13 |
| FY32 | 14.9% ·fade | 250.64 |
| FY33 | 6.0% ·fade | 265.67 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.